Design and in vitro evaluation of formulations with pH and transit time controlled sigmoidal release profile for colon-specific delivery

Drug Delivery

Volumn 16, Issue 4, 2009, Pages 205-213

  Asghar, Laila Fatima Ali ^a   Azeemuddin, Md ^a   Jain, Varun ^a   Chandran, Sajeev ^a,b  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b LUPIN LIMITED   (India)

Author keywords

Acrylate polymers; Colon specific delivery; Delayed release; Ethyl cellulose; Matrix embedding

Indexed keywords

ACRYLIC ACID; CARBOMER; ETHYL CELLULOSE; INDOMETACIN; POLYCARBOPHIL; CELLULOSE; DRUG;

ALKALINITY; ARTICLE; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SCREENING; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; INTESTINE TRANSIT TIME; IONIZATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SIGMOID; CHEMISTRY; COLON; DELAYED RELEASE FORMULATION; DRUG DOSAGE FORM; DRUG EFFECT; DRUG STABILITY; METABOLISM; PH; TIME;

CELLULOSE; CHEMISTRY, PHARMACEUTICAL; COLON; DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; INDOMETHACIN; PHARMACEUTICAL PREPARATIONS; TIME FACTORS;

EID: 70350647236     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540902823960     Document Type: Article

References (42)

1. Rubinstein A. 1995. Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst 12:101-149.
2. Kinget R, Kalala W, Vervoort L, Mooter GU. 1998. Colonic drug targeting. J Drug Target 6:129-149.
3. Basit AW. 2005. Advances in colonic drug delivery. Drugs 65:1991-2007.
4. Hull MA, Gardner SH, Hawcroft G. 2003. Activity of the non-steroidal anti- inflammatory drug indomethacin against colorectal cancer. CancerTreat Rev 29:309-320.
5. Kapitanoviæ S, Aev T, Antica M, Kralj M, Cavri G, Krešimir P, Spaventi R. 2006. Effect of indomethacin on E-cadherin and â-catenin expression in HT-29 colon cancer cells. Exp Mol Path 80:91-96.
6. Mandayam S, Huang R, Tarnawski AS, Chiou SK. 2007. Roles of survivin isoforms in the chemopreventive actions of NSAIDS on colon cancer cells. Apoptosis 12:1109-1116.
7. Fujino H, Chen XB, Regan JW, Murayama T. 2007. Indomethacin decreases EP2 prostanoid receptor expression in colon cancer cells. Biochem Biophys Res Commun 359:568-573.
8. Marsh CC, Sachuna AA, Sundstrom WR. 1986. A review of selected investigational non steroidal anti inflammatory drugs of the 1980s. Pharmacotherapy 6:10-25.
9. Krishnaiah YSR, Satyanarayana S, Rama Prasad YV, Narasimha RS. 1998. Evaluation of guar gum as a compression coat for drug targeting to colon. Int J Pharm 171:137-146. (Pubitemid 29023106)
10. Fernández-Hervás MJ, Fell JT. 1998. Pectin/chitosan mixtures as coatings for colon-specific drug delivery: an in vitro evaluation. Int J Pharm 169:115-119.
11. Akhgari A, Garekani HA, Sadeghi F, Azimaie M. 2005. Statistical optimization of indomethacin pellets coated with pH dependent methacrylic polymers for possible colonic drug delivery. Int J Pharm 305:22-30.
12. Akhgari A, Sadeghi F, Garekani HA. 2006. Combination of timedependent and pH-dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets. Int J Pharm 320:137-142.
13. Ji C, Xu H, Wu W. 2007. In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS 30D-coated colon-targeted pellets of indomethacin. J Drug Target 15:123-131.
14. Sinha VR, Kumria R. 2002. Binders for colon specific drug delivery: an in vitro evaluation. Int J Pharm 249:23-31.
15. Wu B, Deng D, Lu Y, Wu W. 2007. Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. Eur J Pharm Biopharm 67:707-714.
16. Asghar LFA, Chandran S. 2008. Design and evaluation of pH modulated controlled release matrix systems for colon specific delivery of indomethacin. Pharmazie 63:736-742.
17. Ibekwe VC, Liu F, Fadda HM, Khela MK, Evans DF, Parsons GE, Basit AW. 2006. An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans. J Pharm Sci 95:2760-2766.
18. Friend DR. 1991. Colon-specific drug delivery. Adv Drug Deliv Rev 7:149-199.
19. Ashford M, Fell JT, Attwood D, Woodhead PJ. 1993. An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting. Int J Pharm 91:193-199. (Pubitemid 23203152)
20. Perez-Marcos B, Iglesias R, Gomez-Amoxa JL. 1991. Mechanical and drug release properties of atenolol-carbomer hydrophilic matrix tablets. J Contr Rel 17:267-276.
21. Luessen HL, Verhoef JC, Borchard G, Leh CM, de Boer AG, Junginger HE. 1995. Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm Res 12:1293-1298.
22. Saha RN, Sajeev C, Sahoo J. 2001. A comparative study of controlled release matrix tablets of diclofenac sodium, ciprofloxacin hydrochloride and theophylline. Drug Deliv 8:149-154.
23. Sajeev C, Saha RN. 2001. Formulation and comparative evaluation of controlled release diclofenac tablets prepared by matrix- embedding technique, membrane barrier technique and combination of the two. Drug Dev Res 53:1-8.
24. Lin SY, Lin KH, Li MJ. 2001. Micronized ethylcellulose used for designing a directly compressed time-controlled disintegration tablet. J Contr Rel 70:321-328.
25. Lin SY, Lin KH, Li MJ. 2004. Formulation design of double-layer in the outershell of dry-coated tablet to modulate lag time and time-controlled dissolution function: studies on micronized ethylcellulose for dosage form design (VII). AAPS Journal 6(3):Article 17. Available online at: http://www.aapsj.org, Accessed 31 October 2008.
26. Sinha VR, Kumria R. 2003. Coating polymers for colon specific drug delivery: a comparative in vitro evaluation. Acta Pharm 53:41-47.
27. Leong CW, Newton JM, Basit AW, Podczeck F, Cummings JH, Ring SG. 2002. The formation of colonic digestible films of amylose and ethylcellulose from aqueous dispersions at temperatures below 37°C. Eur J Pharm Biopharm 54:291-297.
28. Alvarez-Fuentes J, Fernández-Arévalo M, González-Rodríguez ML, Cirri M, Mura P. 2004. Development of enteric-coated timed-release matrix tablets for colon targeting. J Drug Target 12:607-612.
29. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. 1983. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 15:25-35.
30. Ritger PL, Peppas NA. 1987. A simple equation for the description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Contr Rel 5:23-36.
31. Follonier N, Doelker E. 1992. Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms. STP Pharma Sci 2:141-155.
32. Hinton JM, Lennard-Jonnes JE, Young AC. 1969. A new method for studying gut transit times using radioopaque markers. Gut 10:842.
33. Huang L-L, Schwartz JB. 1995. Studies on drug release from a carbomer tablet matrix. Drug Dev Ind Pharm 21:1487-1501.
34. Taylan B, Capan Y, Guven O, Kes S, Hincall AA. 1996. Design and evaluation of sustained release and buccal adhesive propranolol hydrochloride tablets. J Contr Rel 37:11-20.
35. Valizadeh H, Nokhodchi A, Qarakhani N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, Löbenberg R. 2004. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev Ind Pharm 30:303-317.
36. Sheu MT, Chou HL, Kao CC, Liu CH, Sokoloski TD. 1992. Dissolution of diclofenac sodium from matrix tablets. Int J Pharm 85:57-63.
37. Marvola M, Nykanen P, Rautio S, Isonen N, Autere AM. 1999. Enteric polymers as binders and coating materials in multiple- unit site-specific drug delivery systems. Eur J Pharm Sci 7:259-267.
38. Hosny EA. 1993. Polycarbophil as a controlled release matrix. Int J Pharm 98:235-238.
39. Cooper AM, Doshi DH, Patel MV. 1995. In vitro prolonged release of basic CNS compounds from HPMC and Carbopol 974P hydrophilic matrixes: polymer/drug ionization and counterion effects. Proc Int Symp Contr Rel Bioact Mater 22:288-289.
40. Tiwari SB, Krishna Murthy T, Pai RM, Mehta PR, Chowdary PB. 2003. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS PharmSciTech 4(3);Article 31. Available online at: http://www. pharmscitech.org, Accessed 31 October 2008.
41. Khan GM, Meidan VK. 2007. Drug release kinetics from tablet matrices based upon ethylcellulose ether-derivatives: a comparison between different formulations. Drug Dev Ind Pharm 33:627-639.
42. Tirosh BM, Baloum T, Nassar M, Friedman A, Rubinstein A. 1997. The effect of Eudragit RL-100 on the mechanical and mucoadhesion properties of polycarbophil dosage forms. J Contr Rel 45:57-64.